The latest version of 10993-1 was just issued, and if not read carefully, can lead one to believe a lot of testing is necessary. While I have seen some trends for more testing, with better materials characterization and well written biological evaluations, the amount of testing can be mitigated.
------------------------------
Lisa Olson
Minneapolis MN
United States
------------------------------
Original Message:
Sent: 18-Sep-2018 17:09
From: Gregory Kleinert
Subject: Complement Activation Test
Hi All:
Recently we have seen a large increase the requirement for this test. I was wondering if any of the community has experienced an increase in this or other ISO 10993 test requirements. One request I can chalk up to a reviewers interest area, however, with multiple requests, is there a change in view from the agency? The Complement Activation test is part of the hemocompatibility suite of testing within Biocompatibility mostly towards implanted devices. Performing the entire 10993 suite of tests is way too costly. Any input is appreciated.
------------------------------
Gregory Kleinert
Sr Director
Biocoat, Inc.
------------------------------